Evidence map›Paper›PMID 21849660›Full record

Trial reportJournal of the National Cancer Institute2011

Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.

Kimmie Ng, Shuji Ogino, Jeffrey A Meyerhardt, Jennifer A Chan, Andrew T Chan, Donna Niedzwiecki, Donna Hollis, Leonard B Saltz, Robert J Mayer, Al B Benson and 7 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the National Cancer Institute, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 6 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 6 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. kng4@partners.org
Shuji Ogino
Jeffrey A Meyerhardt
Jennifer A Chan
Andrew T Chan
Donna Niedzwiecki
Donna Hollis
Leonard B Saltz
Robert J Mayer
Al B Benson
Paul L Schaefer
Renaud Whittom
Alexander Hantel
Richard M Goldberg
Monica M Bertagnolli
Alan P Venook
Charles S Fuchs
Dana-Farber Cancer Institute · USHarvard University Press · USDuke Medical Center · USCommunity Hospital · USEdward Hospital · USMemorial Sloan Kettering Cancer Center · USPalmetto Hematology Oncology · USUniversité de Montréal · CAUniversity of California, San Francisco · US

Funding

CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI MAYER, ROBERT J · 2007 to 2023
$33.2M
SOUTHEAST CANCER CONTROL COSORTIUM, INCU10CA045808 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI ATKINS, JAMES NORMAN · 1987 to 2013
$26.6M
MULTIDISCIPLINARY CLINICAL AND TRANSLATIONAL SCIENCE (MCTS) PROGRAM (UL1)UL1RR025741 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GREENLAND, PHILIP · 2008 to 2011
$24.7M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
MEDICAL CENTER OF DELAWARE CCOPU10CA045418 · NCI · CHRISTIANA CARE HEALTH SERVICES, INC. · PI GRUBBS, STEPHEN S. · 1987 to 2014
$14.5M
SOUTHERN NEVADA CANCER RESEARCH FOUNDATION-CCOPU10CA035421 · NCI · SOUTHERN NEVADA CANCER RESEARCH FDN · PI ELLERTON, JOHN A · 1985 to 2014
$9.8M
UNIVERSITY OF ILLINOIS MINORITY BASED CCOPU10CA074811 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PEACE, DAVID J · 1997 to 2011
$8.5M
SYRACUSE HEMATOLOGY-ONCOLOGY CCOPU10CA045389 · NCI · HEMATOLOGY-ONCOLOGY ASSOCIATES/CTL NY · PI KIRSHNER, JEFFREY JAY · 1987 to 2014
$7.4M
NORTH SHORE UNIV COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035279 · NCI · NORTH SHORE UNIVERSITY HOSPITAL · PI VINCIGUERRA, VINCENT P · 1985 to 2014
$7.3M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
NCI NIH HHS CA03927NCI NIH HHS CA04326NCI NIH HHS CA04457NCI NIH HHS CA07968NCI NIH HHS CA08025NCI NIH HHS CA11789NCI NIH HHS CA12046NCI NIH HHS CA16450NCI NIH HHS CA21060NCI NIH HHS CA26806NCI NIH HHS CA29165NCI NIH HHS CA31946NCI NIH HHS CA31983NCI NIH HHS CA32291NCI NIH HHS CA33601NCI NIH HHS CA35279NCI NIH HHS CA35421NCI NIH HHS CA37135NCI NIH HHS CA41287NCI NIH HHS CA45389NCI NIH HHS CA45418NCI NIH HHS CA45808NCI NIH HHS CA47555NCI NIH HHS CA47559NCI NIH HHS CA47577NCI NIH HHS CA47642NCI NIH HHS CA59518NCI NIH HHS CA71323NCI NIH HHS CA74811NCI NIH HHS CA77298NCI NIH HHS CA77406NCI NIH HHS CA77440NCI NIH HHS CA77597NCI NIH HHS CA77651NCI NIH HHS CA77658NCI NIH HHS K07 CA148894NCI NIH HHS P50 CA127003NCI NIH HHS P50CA127003NCI NIH HHS R01 CA137178NCI NIH HHS T32 CA009001NCI NIH HHS T32CA009001-34NCI NIH HHS U10 CA031946NCRR NIH HHS UL1 RR025741
6 · The paper itself

Abstract

backgroundAlthough preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown.

methodsWe conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided.

resultsAmong 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (P(trend) = .63, .63, and .59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (P(interaction) = .84, .67, and .98 for DFS, RFS, and OS, respectively).

conclusionStatin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.

Indexed as

MutationAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingOdds RatioHydroxymethylglutaryl-CoA Reductase InhibitorsKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID21849660
PMCPMC3196479
OpenAlexW2101198015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.